![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Italfarmaco Gains Rare Pediatric Disease Designation for Drug Treating Duchenne Muscular Dystrophy
Italfarmaco Gains Rare Pediatric Disease Designation for Drug Treating Duchenne Muscular Dystrophy
The FDA has granted Italfarmaco a Rare Pediatric Disease designation for Givinostat, its investigational treatment for young males suffering from Duchenne Muscular Dystrophy.
In April, Italfarmaco disclosed positive interim study data indicating a slower disease progression in young males treated with Givinostat and steroids. The company said it has now completed enrollment of 179 participants for a phase 3 trial and expects to release first results in June 2022.
Givinostat previously received Orphan Drug and Fast-Track designations from the FDA.
Upcoming Events
-
21Oct